Clinical Trial - NCT02500199

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Recruiting

Sponsor: Hengrui Therapeutics, Inc.

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT02500199

Protocol Info

Short Description: Phase I of Pyrotinib in HER2+ Cancer
Long Description: A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
MGH Status: Open
Sponsor: Jiangsu Hengrui Medicine Co., LTD
Disease Program: Thoracic

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).
Condition Title Intervention Phase
Breast Cancer Gastric Cancer Solid Tumors NSCLC Pyrotinib Phase 1
Study Type Interventional
Official Title A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

Primary Outcome Measures

Part 1 Maximum Tolerated Dose (MTD) [Time Frame: Day 1 to 28 ( Cycle 1)] [Designated as safety issue: ]

Part 2 Overall Response Rate (ORR) [Time Frame: up to 24 months after the first dose] [Designated as safety issue: ]


Secondary Outcome Measures

Maximum plasma concentration(Cmax) [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Time to Cmax [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Terminal half life (t1/2) [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Area under the plasma concentration-time curve [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Volume of distribution(V/F) [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Plasma Clearance(CL/F) [Time Frame: Up to 3 cycles(each cycle 28 days)] [Designated as safety issue: ]

Progression Free Survival (PFS) [Time Frame: up to 24 months after the first dose] [Designated as safety issue: ]

Estimated Enrollment: 50
Study Start Date: June 2015
Estimated Study Completion Date: March 2021
Estimated Primary Completion Date: September 2020
Arms Assigned Interventions

Experimental:Pyrotinib

A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
Drug:Pyrotinib
Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

The study is open to all males and females who meet the following inclusion criteria at screening and baseline to participate in the study.

To be included to participate in this study each patient must:

  • be ≥ 18 years of age;
  • have an Eastern Cooperative Oncology Group performance status of 0-1 (not declining within past 2 weeks, see Appendix 1);
  • have confirmed HER2 gene amplified tumor fluorescence in-situ hybridization (FISH, HER2/cep17 ratio > 2) or HER2 overexpression (IHC 3+) or documented HER2 gene mutation. Documentation of HER2 status using FDA approved test(s) for HER2 testing specific for HER2 breast and gastric cancer is required prior to screening;
  • for part 1:

1. Patients with HER2 positive (defined as documented overexpression or amplification or mutation) metastatic breast cancer who have experienced disease progression following at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required;

2. Patients with HER2 positive metastatic gastric cancer who have disease progression on prior trastuzumab therapy;

3. other HER2-positive solid tumors (defined as documented overexpression or amplification or mutation) that have no approved targeted agent as standard of care

  • for part 2:

1. Patients with HER2 positive metastatic breast cancer who have experienced disease progression after at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required;

2. Patients with documented HER2 mutated NSCLC whose disease progressed on prior therapy;

3. Patients in Part 2 extension must have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;

  • Left ventricular ejection fraction within institutional limits of normal (by multi gated acquisition scan or echocardiography;
  • have the required screening laboratory values including the following parameters:

1. Absolute neutrophil count ≥ 1.5×109/L (1,500/mm3);

2. Platelets ≥ 75×109/L (75,000/mm3);

3. Hemoglobin ≥ 9.0 g/dL (90 g/L);

4. Total bilirubin ≤ 1.5× upper limit of normal (ULN);

5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; for patients with liver metastases, ALT and AST ≤ 5×ULN;

6. Serum creatinine ≤ 1.5×ULN;

  • have a life expectancy of > 12 weeks;
  • for female patients who are of child bearing potential, a negative serum pregnancy test result before study entry. A female patient of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or other means of birth control or whose sexual partners are either sterile or using contraceptives;
  • and who have provided informed consent by signing the informed consent form.

Main Exclusion Criteria:

Patients who meet any of the criteria listed below will not be eligible for participation in this study. A patient will not be eligible for study participation if:

  • is unable or unwilling to swallow pyrotinib;
  • has been < 2 weeks since the last radiotherapy, chemotherapy, hormone therapy, surgery or molecule-target therapy (< 6 weeks if chemotherapy included nitrosoureas or mitomycin);
  • the bone or skin is the only site of disease (for Part 2 extension only);
  • has pleural or peritoneal only disease;
  • has uncontrolled ≥ grade 2 hypokalemia and hypomagnesemia;
  • has had other cancer(s) within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin;
  • has active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least 4 weeks, and off steroids and anticonvulsants, before first dose of study drug);
  • has either QTcF prolongation (> 470 ms for female and > 450 ms for male), a known history of QTcF prolongation or Torsade de Pointes; or is on drugs that are required for existing medical conditions and that may result in QT prolongation (e.g., anti-arrhythmic drugs); patients who use medications that have a minimal impact on the QTcF interval in the Arizona-CERT criteria are allowed to participate in this study at Investigator's discretion based on his/her clinical assessment);
  • has a significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or ≥ grade 2 diarrhea of any etiology at baseline);
  • has participated in any other investigational drug clinical studies within the last 4 weeks;
  • is concurrently receiving other anti-tumor therapies at time of study screening visit;
  • has an active infection (per Investigator judgment);
  • has a history of immunodeficiency including seropositive for human immunodeficiency virus, or has other acquired or congenital immunodeficient disease;
  • has evidence of uncontrolled heart disease, including (1) congestive heart failure (New York Heart Association functional classification) of ≥ 2), (2) angina requiring treatment (3) myocardial infarction within the past 12 months, or (4) any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention;
  • has allergies or a known history of hypersensitivity to any components of the pyrotinib;
  • is female and of childbearing potential (WOCBP) who is unwilling or unable to use an acceptable method (barrier methods only) to avoid pregnancy for the entire study period and for up to 28 days post last dose;
  • is female and pregnant (or found to be pregnant at screening) or breastfeeding;
  • evidence of significant medical illness or an abnormal laboratory finding, which according to the Investigator's judgment, will substantially increase the risk of participation in and completion of the study. Including, but not limited to, serious ongoing infection (ie, requiring intravenous antibiotic or antiviral agent), uncontrolled major seizure disorder, or significant pulmonary disorder (e.g. interstitial pneumonitis, pulmonary hypertension); hypertension (> grade 3), severe diabetes (uncontrolled > grade 3 hyperglycemia), serious ongoing infection or thyroid disease;
  • has a known history of neurological psychiatric disease including epilepsy or dementia that would interfere with patient's ability to participate in the study or to provide consent;
  • has had prior exposure to any other investigational HER2 targeted agents within 4 weeks of screening visit.
  • is currently taking strong CYP3A4 inhibitor or concomitant meds.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02500199

Locations

  • United States, California
    • University of California, Irvine School of Medicine Orange, California, United States, 92868
    • UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817
  • United States, Florida
    • Florida Cancer Specialists Sarasota, Florida, United States, 34232
  • United States, Massachusetts
    • Massachusetts General Hospital Boston, Massachusetts, United States, 02114
    • Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215
  • United States, Michigan
    • Henry Ford Health System Detroit, Michigan, United States, 48202
  • United States, Missouri
    • Washington University Saint Louis, Missouri, United States, 63110
  • United States, New York
    • Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065
  • United States, Tennessee
    • Tennessee Oncology Nashville, Tennessee, United States, 37203
  • United States, Texas
    • South Texas Accelerated Research Therapeutics San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Hengrui Therapeutics, Inc.

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT02500199
Other Study ID Numbers:
Study First Received:
Last Updated:
Health Authority:

Keywords provided by Hengrui Therapeutics, Inc.:

HER2 positive

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on August 15, 2019